Wells Fargo & Company 9 Meters Biopharma, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.21 - $0.32 $421 - $641	-2,005 Reduced 10.16%	17,723 $3,000
Q2 2022 Aug 12, 2022	SELL	$0.26 - $0.64 $10,012 - $24,646	-38,510 Reduced 66.13%	19,728 $4,000
Q1 2022 May 16, 2022	SELL	$0.52 - $1.0 $41,159 - $79,153	-79,153 Reduced 57.61%	58,238 $35,000
Q4 2021 Feb 14, 2022	BUY	$0.85 - $1.33 $110,631 - $173,106	130,155 Added 1798.71%	137,391 $134,000
Q2 2021 Aug 16, 2021	SELL	$1.04 - $1.5 $1,932 - $2,787	-1,858 Reduced 20.43%	7,236 $8,000
Q1 2021 May 13, 2021	BUY	$0.84 - $2.16 $2,805 - $7,214	3,340 Added 58.05%	9,094 $11,000
Q4 2020 Feb 09, 2021	BUY	$0.65 - $1.11 $63 - $108	98 Added 1.73%	5,754 $5,000
Q3 2020 Nov 05, 2020	BUY	$0.48 - $0.84 $227 - $397	473 Added 9.13%	5,656 $5,000
Q2 2020 Aug 13, 2020	BUY	$0.43 - $0.74 $2,228 - $3,835	5,183 New	5,183 $3,000

67.9K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.